In line with our results, a recent study applying single-cell transcriptomics identified that SMOC2, a member of the SPARC family, showed increased expression in hepatic stellate cells during NAFLD development and in plasma, suggesting that SMOC has potential as a new diagnostic biomarker for NASH patients [45]. Here, SMOC2 is linked to metabolic dysfunction-associated steatohepatitis.